key: cord-0689363-8na0nn5s
authors: Siefkes, D.
title: The origin of HIV-1, the AIDS virus
date: 1993-10-31
journal: Medical Hypotheses
DOI: 10.1016/0306-9877(93)90069-3
sha: d5d44ef92f565d100cb2a7f3681b6595475ea737
doc_id: 689363
cord_uid: 8na0nn5s

Abstract This article proposes a series of experiments to determine if cows and sheep could be used as animal models for HIV-1, the AIDS virus. To justify this effort, a substantial case is presented that HIV-1 is a natural recombinant of Bovine Leukemia Virus (BLV) and Visna Virus. This natural recombinant may have been inadvertently transferred to humans through the Intensified Smallpox Eradication Program conducted in sub-Saharan Africa in the late 1960s and most of the 1970s.

The purpose of this article is to propose a series of experiments to determine if cows and sheep could be used as animal models for Acquired Immune Deficiency Syndrome (AIDS). This would be of assistance in searching for a cure or a vaccine. To justify these experiments, a chain of reasoning is presented that the Human ImmunodeEciency Virus Type 1 (HIV-1) is a natural recombinant of Bovine Leukemia Virus (BLV) and Visna Virus, also known as Bovine ImmunodeEciency-like Virus (BIV) (1) . This natural recombinant was inadvertently transferred to humans through contaminated vaccine used to inoculate millions of Africans against smallpox during the smallpox eradication program conducted in sub-Saharan Africa in the late 1960s and most of the 1970s. These facts have serious implications not only for AIDS research but also for the new technology of 'pharming' (2, 3) , whereby genetically altered cows, sheep, goats and pigs are used to obtain human hormones, proteins, and other drugs.

First, the remarkable correlation between the distribution of AIDS cases in the world and the vaccination program that eradicated smallpox will he discussed. Then facts will be presented regarding BLV, Visna, HIV-1, and the recombination of retrovirus genomes which suggest that the smallpox vaccine manufacturing procedure could have created HIV-l and transmitted it to humans. Finally, the conclusions describe the experiments to establish whether or not cows and sheep could he used as effective animal models for AIDS research.

its abrupt appearance around 1980 was due to people migrating from rural to urban areas. This theory proposes that the virus was then propagated through changing sexual mores, increased use of blood products in the practice of medicine and increased airplane travel. This seems unlikely, however, since the rural to urban migration in Africa has been going on for over 30 years. If HIV-l had been endemic in rural areas, the disease should have appeared well before 1980 in urban areas, and it didn't. The clinicians Biggar (15) interviewed do not believe they could have failed to recognize AIDS as a distinct clinical entity if it had existed prior to the late 1970s or early 1980s.

The growth of HIV-l infections worldwide and in sub-Saharan Africa since the late 1970s and early 1980s has been exponential (20) (Fig. 1) . Thus, because of the long incubation period of HIV-l, as long as 10 years in some cases (21) , we know that the virus had to have been infecting our species sometime in the decade before exponential growth began, i.e. the late 1960s and most of the 1970s. This is precisely the time period of the Intensified Smallpox Eradication Program.

Numerous authors have documented the high incidence of AIDS in Haiti and the possible transmission of some cases of AIDS into the United States by means of sexual contact with Haitians (19, (22) (23) (24) (25) (26) (27) (28) . This is associated with Zaire, because there were thousands of Haitians in Zaire providing technical and teaching assistance to help the French-speaking people of Zaire after the Belgians left (23) . There is one unconfirmed report that many of these Haitians were vaccinated against smallpox (29) simply because they were present during the time the smallpox eradication progmm took place. In any case, the time of appearance of AIDS in Haiti corresponds with the return of these professionals to Haiti (29, 30).

The American Red Cross is also aware there was something about those sub-Saharan African countries and Haiti that led to a high incidence of AIDS. For many years in the 1980s the Red Cross had the following question on the form to be signed before donating blood, ' (31) , knew as early as the mid-1980s that the incidence of AIDS in sub-Saharan Africa and Haiti was exceptionally high. This, while not conclusive, is further indication that the origin was sub-Saharan Africa.

Bovine Leukemia Virus (BLV) is an RNA retrovirus (32) which causes an immunosuppressive infection of cattle and sheep by replicating in the cells of the immune system (33) . Its provirus is 87 14 base pairs long (34) . Normally, it takes 4-S years (32) for symploms of the disease to manifest themselves from the date of the infection, but the virus can be transmitted at any time after it enters the animal's bloodstream. Because it is slow acting and there are no visible signs of the disease, many animals remain in the preclinical stage for their entire lifetimes (32) . Diagnosis before the onset of symptoms is by means of an ELISA (enzymelinked immunosorbent assay) test (35) for antibodies to BLV similar to one of the tests used for detecting antibodies to HIV-l in humans. When the infection finally appears, two of the most common symptoms are lymphadenopathy -enlargement of the superficial lymph nodes -and a chronic, persistent diarrhea (32) . After that, various cancers and diseases can infect the digestive tract, the heart, the nervous system, and other organs of the animal's body. This is similar to AIDS in humans.

The major modes of BLV transmission (36) are contaminated hypodermic needles used in blood transfusions and vaccinations, ear-tag applications and dehorning using the same equipment, rectal palpation using the same polyethylene sleeve from animal to animal, horseflies and colostrum from a scropositive mother to its offspring. In short, any mechanism that can transfer blood or any lymphocyte containing bodily fluid into the blood stream of another cow or sheep can transmit this disease. Johnson (36) has shown conclusively that as little as 1 pl of blood (a fraction of a drop) from a seropositive cow injected into calves intramuscularly, intravenously, subcutaneously or intradermally causes se-reconversion within as little as 4 weeks after inoculation. In other words, a small blood to blood transfer or, more precisely, a small infected lymphocyte to blood transfer is enough to transmit BLV.

In 1985, Ratner et al (37) reported a nucleotide sequence homology of 62% between the long terminal repeat (LTR) sequences of BLV and HIV-l. Also in 1985, Sodroski et al (38) reported that HIV-l shares with BLV a phenomenon connected with these LTR sequences, known as truer-acting transcriptional regulation. They believe this greatly speeds up the fate of gene replication which may account for the virulence of HIV-I infection.

Visna is a slow acting, pathological disease first reported in sheep in Iceland in 1935 (39) . (The word Visna is an Icelandic word meaning wasting or shrinking.) It is caused by an RNA retrovirus of the subfamily Lentivirinue or slow-acting viruses (40) , and its provirus is 9202 base pairs long (41). This disease was first shown to infect cattle by Van der Maaten, Seger in 1972 and 1974 (42,43) . Gonda et al, in 1985 and 1987 (1, 44, 45) , clearly demonstrated a genetic, structural and serologic relationship between HIV-1 and Visna. Many authors (41, (46) (47) (48) (49) (50) (51) (52) have confirmed this close relationship between HIV-I and Visna, and HIV-1 is now considered to be a member of the lentivirus subfamily (41, 53) .

Like BLV and HIV-l, Visna may take years of incubation (32, ~~805807, 54) before symptoms of the disease appear, and many infected animals with no conspicuous clinical signs are slaughtered (55) . When symptoms do occur, two of the most common in sheep are a chronic persistent pneumonia and significant weight loss (39, 40) . Both of these symptoms are common in human patients with AIDS. Like HIV-l (56), Visna crosses the blood-brain barrier and is found in brain cells and cerebral spinal fluid (57, 58) . At autopsy, CNS lesions of chronic meningitis and demyelination are observed over the spinal cord and portions of the brain (40) . Like BLV and HIV-l, tests for antibody to Visna must be performed by the veterinarian to confirm the existence of this disease prior to the onset of clinical symptoms (40) .

The transmission of Visna has been studied less than that of BLV, but it is felt that hypodermic needles contaminated by using one needle for multiple injections is one cause (54) . Another is viral infected lymphocytes in the colostrum being passed to the newborn (40) . Again, the transfer of even small amounts of contaminated blood or lymphocytes to the bloodstream of another animal is suspected of transmitting this virus.

In 1985 Gonda (44) reported that 35% of the genome of HIV-l was heteroduplexed (essentially identical) with Visna, a degree of homology he called 'striking'.

BLV is widespread in the United States and around the world (59) . In Florida, antibodies to BLV were detected at a level of 48% in 7768 dairy cattle and 7% in 49 11 

Thus, we have two animal diseases whose clinical symptoms are essentially identical to the clinical symptoms of AIDS. The T-cell (immune cell) affinity that AIDS demonstrates corresponds to the immunosuppressive characteristics of BLV. The dementia associated with AIDS corresponds to the ability of Visna to enter the brain (56) , and the weight loss and pneumonia associated with AIDS correspond with the weight loss and pneumonia of Visna. Additionally, both retroviruses show a significant degree of nucleotide sequence homology to HIV-I and, structurally, HIV-l is indistinguishable from the lentivirus subfamily to which Visna belongs (44) .

Consequently, it is reasonable to conjecture that HIV-l was formed by BLV and Visna combining together in some manner and being transferred to humans. How could this have occurred? The answer lies in the rapid rate of genetic divergence of RNA viruses and in the production method for Vaccinia, the vaccine used to immunize humans against smallpox.

The rate of genetic divergence of RNA viruses in general is very rapid (63) . Studies have shown that the rate of divergence of RNA viral genomes at the nucleotide level is as high as 0.03-2.0% per year (64) . This is in striking contrast to the divergence rate in the DNA gcnomes of animals and humans, approximately 1% per million years (65) . In other words, some RNA viruses diverge as much as a million times faster than human DNA. James and Ellen Strauss (66) have pointed out that this rapid RNA sequence divergence rate has important implications for RNA viruses as disease pathogens.

One of the ways in which this divergence manifests itself is in recombinatiowthe exchange of gene segments between two parental viruses during a mixed infection to form offspring with characteristics from both parents (66) . It has been shown in the laboratory that true recombination occurs among the picornaviruses and the coronaviruses (63). Hahn, Lustig, E. Strauss and J. Strauss (67) have shown that westem equine encephalitis virus (WEEV), a 'successful' widespread virus which causes encephalitis in humans, is a natural recombinant of eastern equine encephalitis virus (EEEV) and a Sindbis-like virus. RNA recombination is now considered to be an important force in the evolution of all types of RNA viruses (63, 67) . In the special case of retroviruses which contain two molecules of single-stranded RNA and reverse transcriptase (RT) in their core, it has been shown (68) that they undergo the highest rate of recombination of any biological system known. (BLV, Visna, and HIV-1 are such retroviruscs.) A typical experiment is to infect a cell culture with two genetically different retroviruses and then examine the offspring after a few replication cycles. As many as 40% of the progeny can be found as recombinants (69) , in that all contain nucleotide sequences derived from each parent. Genetic experiments with two avian retroviruses (70,7 1) have shown that the frequency of recombinant virus from mixed infections exceeds 10%. Hunter (70) proposed the formation of a heterozygote virus from a coinfected cell which then would produce the recombinant virus during the second cycle of infection as shown in Figure 2. 2. HIV-1 contains sequences from both BLV and Visna as a natural recombinant would.

3. All three are members of the same retroviral family, retroviridae (72).

It is well known that Vaccinia virus replicates in humans, cows and sheep. The antibodies produced against this virus protect humans against Variola, the smallpox virus. In order to manufacture smallpox vaccine, the following steps are generally followed (73, 74):

1. Shave the skin of a cow or a sheep, called the vaccinifcr, and disinfect the skin with soap and water and/or quartemary ammonium salt or alcohol.

The exact mechanism by which this recombination occurs is subject to some debate (68, 70, 71) , but the fact that recombination does occur from retroviral coinfected cells after multiple cycles of infection is not in dispute.

Amborski's demonstration (62) that BLV and Visna coinfect cattle in nature does not prove that these viruses coinfect the same cells, but it does strongly suggest the possibility. If BLV and Visna coinfect the same cells, HIV-l would be a possible recombinant. This is supported in addition by the following facts: 1. The genomes of all three are approximately the same size (BLV-8714 nucleotides, Visna-9202, and 2. Scarify the skin with a scarifying instrument which looks like a narrow ice scraper with 7 or 8 sharp needles on the end with the points approximately 5 mm apart, so that when drawn across the skin it leaves 7 or 8 parallel cuts in the skin roughly 5 mm apart. This scarification is made horizontally, vertically and then diagonally over the same area. Successive areas approximately a foot square are usually done on the abdomen and flanks.

3. The seed lot Vaccinia virus is thoroughly rubbed into the scarified areas and allowed to grow for 4 days at which time the skin is again thoroughly washed with soap and water to remove any bacteria. The animal is then killed humanely and the blood washed from its body in order to obtain water clear vaccine.

4. The vaccine 'pulp' is harvested by using a scoop HIV-l-9749 (37)).

shaped instrument similar to a sharpened spoon to scoop out the infected areas from the scarified portions of the vaccinifer's epidermis. 5. This pulp is then processed by homogenizing it with a fluorcarbon in a blender, centrifuging it to form a clear aqueous phase, and treating it with phenol to kill any bacteria which might have been picked up in the process. The resulting clear 'lymph' is then ready to be freeze-dried or used as the vaccine.

Practically all of the vaccine used in the Intensified Program was freeze-dried for shipment, reconstituted in the field, and injected into humans (4). This injection was a lymphocyte to blood transfer from cows and sheep to humans.

Simple mechanical transfer is a means by which the above procedure could transmit HIV-l to the vaccine and then to humans. HIV-l has been isolated from epidetmal Langerhans cells of human AIDS patients (75) , and Langerhans cells, which are an important part of the immune system (76) are common to the epidermis of mammals (77) . Consequently, if HIV-l was already in the vaccinifcr, some of it would be in its epidermis. Vaccinia virus was grown in the epidermis of the vaccinifer, and even if the Vaccinia virus did not coinfect a cell already infected with HIV-l, some HIV-l contaminated cells would be picked up during the 'scooping out' of the infected portions of the vaccinifer's skin and transferred to the vaccine. It was standard procedure (74) to pool individual harvests from one animal with harvests from others to achieve a minimum volume for freeze-drying, and 400 doses of vaccine (0.0025 ml each) could be obtained from 1 ml of vaccine using bifurcated needles (4, ~569). Thus, a significant amount of vaccine could have been contaminated from even one diseased animal.

If Vaccinia virus coinfects a cell already infected with HIV-l, there is a possible mechanism by which the amount of HIV-l in the epidermis of the vaccinifer might be increased before harvest. This mechanism is the integration of HIV-l into the Vaccinia gcnome.

HIV-l (78), upon entering the host cell, has its RNA transcribed by RT into proviral DNA which exists in three forms-a linear form with one long terminal repeat (LTR) sequence at each end, a circular or plasmid form with two LTRs and a circular or plasmid form with one LTR (Fig. 3) . This proviral DNA is then integrated into the host ~11's nuclear DNA where it directs viral replication to continue the life cycle of the virus.

Brown et al (79) show that this integration is dependent on the LTR seqeunces of the proviral DNA, and it is quite possible that the circularized (plasmid) 2-LTR form of the proviral DNA is the immediate precursor to the integrated DNA. It is important to note that a significant amount of unintegrated DNA remains in the cytoplasm of the host cell in all three forms-linear with one LTR at each end, 2-LTR circular, and l-LTR circular (78) . It should also be noted that this mechanism of infection, life cycle, and retention of proviral DNA in the cytoplasm is identical to that of Visna virus (80, 81) .

It is also known that Vaccinia virus can coinfect cells already infected with RNA viruses (82) , and that Vaccinia's transcription and translation take place totally in the cytoplasm of the host cell (82, 83) . The first step after infection is the uncoating of the Vaccinia virus core (84) . Thus, if Vaccinia coinfected an already HIV-I infected cell during vaccine manufacture, the uncoated Vaccinia virus DNA core would then be in the cytoplasm of the HIV-I infected cell along with the 2-LTR circularized form of proviral HIV-l DNA. This 2-LTR circularized HIV-l DNA could then integrate itself into the Vaccinia genome by the same procedure it used to integrate itself into the host cell's genome originally.

This would be analogous to the work of Fenner, Mackett, Smith, Moss and Paoletti et al (83) (84) (85) (86) (87) (88) (89) (90) who have shown the ability of Vaccinia virus to serve as a foreign gene expression vector. By constructing plasmids containing a foreign gene under the control of a Vaccinia virus promoter flanked by Vaccinia virus DNA, many foreign genes have been inserted in to Vaccinia and expressed from Vaccinia virus recombinants (82) (83) (84) (85) (86) . Panicali, Paoletti, and Perkus (87) (88) (89) (90) have shown that there are at least 13 sites on the Vaccinia genome where genes can be inserted without interfering with the ability of Vaccinia to replicate. They also showed that this integration of foreign genes into Vaccinia and their subsequent expression can be achieved without directly engineering Vaccinia promoters. It is, therefore, reasonable to conclude that the 2-LTR sequences on the plasmid form of HIV-1 could serve as the promoter for the integration of the entire 9749 bp HIV-l genome into the Vaccinia virus DNA. Because the Vaccinia virus genome is large, about 187 000 base pairs (82) , it has the capacity to accept genes containing as many as 25 000 base pairs (91) . Thus, there is more than adequate room for this integration to take place. Once it does, HIV-1 could be expressed in that cell or by the next cell that the Vaccinia/HIV-1 recombinant infects. This suggested mechanism would increase the con-2. It explains why the disease in Africa occurred centration of HIV-1 in the epidermis of the vaccinifcr with approximately equal frequency in men and beyond its concentration in the absence of the Vacwomen (92, 93) , since there were roughly equal numcinia infection.

bers of men and women in the vaccination lines.

We now have the following theory for how AIDS was created: at least one of the cows and sheep used in the manufacture of smallpox vaccine, unknown to Chose conducting the procedure, was coinfected with BLV and Visna at the stage in their development when visible symptoms of the associated diseases were not yet present. The animal or animals would have appeared healthy, but the BLV and Visna had already naturally recombined into HIV-l. The concentration of HIV-l in the epidermis of the vaccinifer may or may not have been increased during the 4 days of Vaccinia infection by the mechanism discussed in the previous section. In either case, the HIV-1 was then transmitted to the vaccine along with the Vaccinia virus and subsequently to humans during vaccination.

3. It explains why the disease was so prevalent in Haiti but not in the Dominican Republic, which shares the same topography, climate and island.

4. Jt explains the complexity of the AIDS virus without it having gone through thousands of years of evolution, an issue raised by Montagnier (17) . 5 . It explains why the decade of the 1970s was critical for the introduction of this virus into humankind. This was the time period of the smallpox inoculations.

6. It explains why some countries such as Ethiopia and the Sudan that participated in the Intensified Eradication Program did not have a problem with AIDS. Only a part of the smallpox vaccine was contaminated. The manufacturing process is a batch process, and we can conclude that only some of the batches of vaccine that went to Zaire, Zambia, Rwanda, Burundi, Malawi, Tanzania and Uganda were contaminated. What does this theory explain?

1. It explains why we have no immunity to HIV-l. It is basically an animal disease.

Weak points of this theory 1. It does not explain some of the early reported cases of AIDS, especially the case of Robert R, a St Louis teenager who died in 1969 of a disease that was identical to or at least closely related to HIV-1 (94, 95) . The early date of this case suggests a conflict with this theory, but this is not clear. We do not know enough about Robert R's medical history. There have also been reports of positive antibody tests to HIV-1 in frozen blood samples from Africa prior to 1969 (96). However, this is not conclusive since these test results may follow from prior exposure to malaria or to human leukocyte antigen due to pregnancy (97) (98) (99) (100) . Additionally, the positive test results reported in one study came from children who had been vaccinated against smallpox in Upper Volta (96).

2. It does not explain the origin of HIV-2, another human retrovirus capable of causing AIDS that is more homologous to simian retroviruses than HIV-l (19, 101) . At this time we can offer only the following note that may eventually lead to a resolution of this issue: the smallpox vaccination program in approximately 20 countries of Central and Westem Africa (102) at the beginning of the Intensified Program from 1967 -1971 used vaccine supplied and manufactured under bilateral agreements with the United States Agency for International Development (103) . Today the prevalence of HIV-2 is highest in those Central and West African countries where these bilateral programs took place (104).

3. It does not explain why AIDS has appeared now, and not previously. We have, after all, used this same method of vaccinating against smallpox for almost 200 years. This is perhaps the strongest argument against this theory. However, the creation of AIDS was a small likelihood event. It required the presence of both BLV and Visna in one animal, and it required the use of that animal as a vaccinifer for the production of Vaccinia virus. Furthermore, since the veterinary literature does not define BLV as a known virus until the late 1960s and early 1970s (105-109), since BLV is exogenous to cattle (1 lo), and since the first report of Visna in cattle did not occur until 1972, it may be that BLV and Visna simply were not present in the animals used as vaccinifers.

On the other hand, it is entirely possible that other human diseases might have been created in this manner, and we are not aware of it. For example, one author (57) has noted some similarities between Visna and human demyelinating diseases such as multiple sclerosis, and the National Multiple Sclerosis Society has supported research on Visna virus (111) . Other authors have noted an evolutionary relationship between BLV and human T-cell leukemia viruses (112) .

HIV-l is a natural recombinant of BLV and Visna virus inadvertently transferred to humans through the procedure by which Vaccinia virus, grown in coinfected cows and sheep, was used to manufacture the vaccine that inoculated millions of Africans against smallpox in the late 1960s and the 1970s.

A low cost, plentifully available animal model for AIDS would be of great assistance in developing a cure or a vaccine. The Gibbon ape and chimpanzee (53, 113, 114) are infectable with HIV-l. However, neither of these animals is plentiful enough for the experimental work that needs to be done, and even those infected years ago do not develop clinical symptoms (115) . More recently, rabbits (116) and pigtail macaques (117) have shown promise as animal models for defining the initial stages of HIV-1 infection, but it is not yet clear that either of these animals will serve as a means of study to reduce or eliminate the disease in infected persons. To do that, it would be helpful if the animal would develop clinical symp toms after seroconversion (118) .

It is proposed that a study be undertaken to determine whether cows and sheep can be used as animal models for HIV-l. (To the author's knowledge, this has not yet been done.)

This would involve screening a variety of species of cows and sheep to certify them free from BLV and Visna and dividing them into three groups. Group 1 would be the control group. Group 2 would be directly injected with human HIV-l virus. Perhaps these animals would develop antibodies to HIV-l and sub sequent symptoms of AIDS.

Group 3 would be used in an experiment which essentially reverses the methodology of making smallpox vaccine described above. Human tissue culture known to contain HIV-1 would be deliberately infected with Vaccinia and allowed to incubate for 4 days. This mixture would then be directly injected to see if antibodies to HIV-1 and subsequent AIDS symptoms develop. This latter procedure also could be tried with smaller animals such as shrews, mice, hamsters, guinea pigs and various monkeys which have not seroconverted after direct injection of HIV-1 blood components (119, 120) . If successful, these experiments would yield an animal model for HIV-1 which will assist AIDS research.

Pharming is a new process using genetically altered cows, sheep, goats and pigs to produce human hormones and other drugs from their milk or blood. In the light of the danger of this technology generat- 

HIV infection in the Dominican Republic-Letters to the Editor and Reply

Characterization 46-47. and molecular cloning of a bovine lentivims related to human 29. Wright P. Smallpox vaccine 'triggerred Aids virus' London immunodeficiency vi&s

Pharmers' who breed cows that can make 30. 'lbcmoson L. Like no other human disease. Washington Post, drugs

SmalIpox vaccine and vaccination in the intensified smallpox eradication programme

The global eradication of smallpox. Geneva: World Health Organization

Global programme on AIDS: current and future dimensions of the HIV/AIDS pandemic-a capsule summary

In point of fact&e global HIV/AIDS situation. Geneva: World Health Organization

Aids in a Danish surgeon

Acquired immune deficiency syndrome in black Africans

Acquired immune deficiency syndrome in France

Multiple opportunistic infection due to AIDS in a previously healthy black woman from Zaire

Virus of fear. Houston Chronicle Sept 15

The Columbus of AIDS

The AIDS problem in Africa

My life stalking AIDS

Virus hunting

The international epidemiology of AIDS

Immunopathogenesis of HIV Infection

AIDS-A new disease's deadly odyssey

The discovery of AIDS: perspectives frcm a Sept 4

Revised recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. Memoranda to Blood Establishments

Veterinary medicine

Transcriptional activation of Bovine leukemia virus in blood cells from experimentally infected asymptomatic sheep with latent infections

Complete nucleolide sequence of the g&me of bovine leukemia virus: its evolutionaty relationshio to other retrovimses

An ELISA for the diagnosis of bovine leukaemia virus infection

Bovine leukemia virus. Part II. Risk factors of transmission. Ccsnpendium on Continuing Education for the Practicing Veterinarian

Complete nucleotide sequence of the AIDS virus, HTLV-III

Truns-Acting transcriptional regulation of human T-cell leukemia virus Type III long terminal repeat

Veterinary pathology, 5th ed. Philadelphia: Lea & Febiger

Swift's Diseases of sheep

Nucleotide sequence of the Visna Lentivims: relationship to the AIDS virus

Isolation of a virus from cattle with persistent lymphocytosis

Ultrastmctural studies of a Visna-like syncytia-producing virus from cattle with lymphocytosis

Narayan 0, Gilden R V. Sequence homology and morphologic similarity of HTLV-III and Visna Virus, a pathogenic Lentivims

Retroviruses of human AIDS and related animal diseases

Ungulate Lentiviruses: pathogenesis and relationship to AIDS. In: Perk K, ed. Advances in veterinary science and comparative medicine

Bovine visna virus and the origin of HIV

Bovine visna virus and the origin of HIV

Lymphadenopathy/AIDS virus: genetic organization and relationship to animal Lentiviruses

Human T-cell lymphotropic virus type iI1 shares sequmce homology with a family of pathogenic lmtiviruses

Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses

lmmunohistochemical staining of cells in the brain of a patient with acquired immune deficiency syndrome (AIDS) with a monoclonal antibody to visna virus

AIDS: animal retrovirus models and vaccines

International mcyclopaedia of veterinary medicine

A 5-year serological study of natural transmission of maedi-visna virus in a flock of sheep, completed with post mottem investigation

HTLV-III infection in brains of children and adults with AIDS encephalopathy

A demyelinating transmissible disease of sheep

The slow infection caused by Visna Virus

Bovine leukemia virus. Part I. Descriptive epidemiology, clinical manifestations, and diagnostic tests. Compendium on Continuing Educatioo for the Practicing

Report of the Committee on Bluetongue and Bovine Retrovirus

Serological detection of multiple retroviral infections in cattle: bovine leukemia virus, bovine syncytial virus and bovine visna virus

Virus evolution

The mutation rate and variability of eukaryotic viruses: an analytical review

Rates of DNA sequence evolution differ between taxonomic groups

Western equine encephalitis virus is a recombinant virus

Retroviridae and their replication

Structure, replication and recombination of retrovirus gmomes: some unifying hypotheses

The mechanism for genetic recombination in the avian retroviruses

DNA H structures: displacement-assimilation model of recombination

Methodology of freeze-dried smallpox vaccine production

Epidermal langerhans cells-a target for HTLV-III/LAV infection

The fascinating story that began in 1868

cell lineage, ontogeny, tissue distribution, and kinetics of Langerhans Cells

The molecular biology of HIV infection: clues for possible therapy

Correct integration of retroviral DNA in vitro

The synthesis and structure of Visna Virus DNA

Narayan 0. A physical map of the linear unintegrated DNA of Visna Virus

Use of Vaccinia Virus as an infectious molecular cloning and expression vector

Vaccination: Its birth, death and resurrection

Vaccinia virus: a tool for research and vaccine development

Vaccinia virus expressicm vectors

General method for production and selection of infectious Vaccinia virus recanbinants expressing foreign genes

Construction of live vaccines using genetically engineered poxvimses: biological activity of Vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant Vaccinia virus expressing influenza vims hemagglutinin

Recombinant Vaccinia virus: immunization against multiple pathogens

Genetically engineered poxviruses expressing multiple foreign genes

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA

AiDS in Africa: an epidemiologic paradigm

Epidemiology of HIV infection in Africa

Documentation of an AIDS virus infection in the United States in 1968

Antibodies reactive with HTLV-III found in freezer-banked sera from children in West Africa

ELISA HTLV retrovirus antibody reactivity associated with malaria and immune complexes in healthy Africans

HLA DR4 antibodies cause positive HTLV-Ill antibody ELISA results

Antibodies and HI'LV-III antibody ELISA testing

Antibodies Detected by Elisa HTLV-III antibody kits

Origin and evolution of HlVs and their role in AIDS pathogenesis

Smallpox and its eradication. Geneva: World Health Organization

Regional smalIpox eradication and measles control in Africa. CDC/Agency for Inter Develop, Document AIR 614

The AIDS knowledge base

Virus-Iike particles in phytohemagghrtinin-stimulated lymphocyte cultures with reference to bovine lymphosarcana

Precipitating antibody to an internal antigen of Ihe C-type virus associated with bovine lymphosarcoma

Evidence of bovine C-type virus in dairy cattle

Bovine lymphosarcoma (LeukemiabA synopsis

Infectivity of bovine C-type (Leukemia) virus for sheep and goats

Experiments with cloned complete tumor-derived bovine leukemia virus information prove that the virus is totally exogenous to its target animal species

Molecular cloning of unintegrated visna viral DNA and characterization of frequent deletions in the 3' terminus

Bovine leukemia virus: unique structural features of its long terminal repeats and its evolutionary relationship to human T-cell leukemia virus

Animal models for acquired immunodeficiency syndrcme

Infection of chimpanzees by human T-lymphotropic retroviruses in brain and other tissues from AIDS patients

The science of AIDS. New York: W II

Infection of rabbits with human immunodeficiency virus 1

Infection of Macoca nemestrina by human immunodeticiency virus Type-l

Development and evaluation of a vaccine for human immunodeficiency virus infection

AIDS and other manifestations of HIV infection

Small animals are not susceptible to human immunodeficiency virus infection